weight watchers ceo weight loss review

WeightWatchers, now known as WW, has launched a new program called the WeightWatchers GLP-1 Program that targets consumers who use GLP-1 medications, a class of drugs originally developed as treatments for Type 2 diabetes, though they have since been approved for the treatment of chronic management of weight as well. The program offers "tailored behavioral support for individuals on a GLP-1 medication." Examples of these medications include semaglutide – the active ingredient in Novo Nordisk's Ozempic, Rybelsus, and Wegovy – as well as tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound medications. The company is seemingly trying to capitalize on the hype after facing financial headwinds. WeightWatchers only recently successfully returned to subscriber growth, CEO Sima Sistani said in the company's latest earnings report.